KENNEWICK, Wash., June 28, 2006 (PRIMEZONE) -- Robert E. Schenter, Ph.D., has accepted the chairmanship of the Scientific Advisory Board for Advanced Medical Isotope Corporation (Pink Sheets:ADMD). Dr. Schenter has over 25 years' experience in the area of radioisotope production for applications in the treatment and diagnosis of major diseases, such as cancer, heart disease, and arthritis. With more than 35 years' experience in the use and production of nuclear data as applied to fission reactor systems, Dr. Schenter brings a legacy of successful application to nuclear technology projects. Dr. Schenter has been the site manager for production of medical isotopes at Westinghouse Hanford and at The Department of Energy's Pacific Northwest National Laboratory.
Selected as a Fellow of the American Nuclear Society, Dr. Schenter is currently a member of the Nuclear Regulatory Commission's Advisory Committee on the Medical Uses of Isotopes. Other associations that Dr. Schenter is active with include his participation as Chair Emeritus of the Fighting Children's Cancer Foundation, and his position as Executive Director of the National Association of Cancer Patients.
Dr. Schenter states, "I know what ADMD is currently working towards, and I am very excited about assisting in commercializing these major medical advances that I consider to be leading edge science going into the 21st century."
"Advanced Medical Isotope is honored that Dr. Schenter has agreed to be an integral part of the future advancement of our company, and I look forward to working with him in bringing our organization to the next level," said Interim CEO James C. Katzaroff.
About Advanced Medical Isotope Corporation ("ADMD")
ADMD is engaged in the development of manufacturing equipment and new techniques for the production of advanced medical isotopes used in the diagnosis and treatment of disease. The company is also developing nuclear power technology that produces proliferation-resistant fuels that do not produce plutonium and long lived transuranic wastes during reactor operation.
Except for historical information contained herein, the matters set forth in this press release, such as statements relating to the company's ability to drive technological developments and the acceptance and timing of product introductions, are forward-looking statements that are subject to risks and uncertainties, including but not limited to, timely development and acceptance of new products, the impact of competitive products and pricing, the timely development and release of products by suppliers, and other risks.